These data underlie the use of viral envelope glycoproteins Gn and Gc (both targets of nAb)8,28 as the main components of candidate RVF vaccines in development.5,6,10 These envelope glycoproteins are important for viral attachment and entry into cells and exhibit limited genetic diversity such that nAb generated by vaccination or natural infection provide cross-protection against heterologous virus strains/lineages.8,29. The gene discussed is GC; the disease is infection.